AI
ACOR

Analytic Investors’s Acorda Therapeutics ACOR Stock Holding History

Analytic Investors’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-64
Closed -$255K – 584
2013
Q2 		$255K Buy
+64
New +$264K ﹤0.01% 517

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Analytic Investors's ACOR Position: Q3 2013 in Review

Analytic Investors sold out of Acorda Therapeutics (ACOR) in Q3 2013, closing a stake of 64 shares — an estimated $255K sold.

Analytic Investors first reported a position in ACOR in Q2 2013 and held it in 1 quarter. The position peaked at $255K in Q2 2013. 153 funds tracked by Wall St. Rank hold ACOR as of Q3 2013.

  • Analytic Investors reported no remaining Acorda Therapeutics position as of Q3 2013 after selling out during the quarter.
  • Analytic Investors sold 64 Acorda Therapeutics shares in Q3 2013, an estimated $255K.
  • Analytic Investors first reported a position in Acorda Therapeutics in Q2 2013 and held it in 1 quarter.
  • Analytic Investors's Acorda Therapeutics position peaked at $255K in Q2 2013.
  • 153 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q3 2013.

Based on Analytic Investors's 13F filing for Q3 2013, filed 12 Nov 2013.